English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduTwo new models, developed by researchers in the lab of Li Wang, PhD, associate professor of radiology in the UNC School of Medicine, can produce more accurate and reliable analysis of brain structures, which is critical for early detection, medical diagnosis, and neurological research.
Tag: Clinical Trial
Helmsley Charitable Trust Awards $3 Million Grant to Research Epithelial Healing in Crohn’s disease
he Helmsley Charitable Trust has awarded a grant of $3,035,566 to support groundbreaking research on Crohn’s disease, to be led by a collaborative team of leading researchers across three institutions. Louis J. Cohen, MD, Assistant Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai; Parakkal Deepak, MD, Associate Professor of Medicine (Gastroenterology), Washington University School of Medicine; and Andres J. Yarur, MD, Associate Professor of Medicine (Gastroenterology), Cedars-Sinai Medical Center, will serve as co-investigators.
Roswell Park Team Identifies Factors That Boost Effectiveness of Immunotherapy in Recurrent Ovarian Cancer
A study led by Roswell Park provides new insight into the complex interactions of the “tumor-immune-gut axis,” and its role in influencing immunotherapy responses in patients with recurrent ovarian cancer. Newly published in Nature Communications, the findings emphasize the role of the patient’s microbiome — the collection of microorganisms in the body —and lay the groundwork for future clinical trials aimed at improving treatment outcomes.
Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.
First-ever randomized clinical trial uses telehealth for suicide prevention
Brief cognitive behavioral therapy for suicide prevention – when delivered remotely via video telehealth – reduces suicide attempts and suicidal ideation. The Ohio State University Wexner Medical Center and College of Medicine led the study that is published online in the journal JAMA Network Open.
Research Shows Cleveland Clinic’s Therapeutic Virtual Yoga Program Can Be Effective for Chronic Low Back Pain
Cleveland Clinic researchers found that a 12-week therapeutic virtual yoga program for chronic low back pain can be a feasible, safe and effective treatment option. The findings are published in JAMA Network Open.
High-Impact Clinical Trials Generate Promising Results for Improving Kidney Health: Part 1
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.
Sarasota Memorial Research Institute Participates in Groundbreaking Prostate Cancer Imaging Study
Prostate cancer is the most common non-skin cancer in men in the US, and the 4th most common tumor diagnosed worldwide. As part of its commitment to improving the diagnosis and staging of this disease, Sarasota Memorial Research Institute is proud to announce its participation in the Solar-Stage study sponsored by Curium.
Teal Health is Awarded a $1.68 Million SBIR Grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) for At-Home Cervical Cancer Screening
Teal Health, a woman-led company on a mission to get all women and people with a cervix in the US screened for cervical cancer, has been awarded a $1.68 million Small Business Innovation Research (SBIR) Direct to Phase II Grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
RESULTS: Study on Advanced-Stage Hodgkin Lymphoma Published in the New England Journal of Medicine
October 17, 2024 – Groundbreaking results from a clinical trial evaluating a novel treatment for advanced-stage classic Hodgkin lymphoma were published today in the New England Journal of Medicine (NEJM). The study, titled “Nivolumab-AVD in Advanced-Stage Classic Hodgkin Lymphoma,” introduces…
Penn Medicine and Children’s Hospital of Philadelphia Create mRNA Vaccine to Prevent and Treat C. difficile
A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff. In animal models, this first mRNA-LNP C. difficile vaccine was found to protect against C. difficile first-time infections and relapsing infections by inducing a robust immune response, promote clearance of existing C. diff bacteria from the gut, and even overcome deficits in host immunity to protect animals after infection.
For multiple sclerosis, medication and cognitive behavioral therapy can reduce fatigue
In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in significant improvements in fatigue. Researchers say the findings could shape treatment approaches to one of the most challenging symptoms experienced by people with multiple sclerosis.
IMRT and proton therapy offer equally high quality of life and tumor control for people with prostate cancer
People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated radiation therapy (IMRT) — achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Cleveland Clinic Study Is First to Show Success in Treating Rare Blood Disorder
CLEVELAND: A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide.
Vandria closes Series A round at CHF28.3m
Hevolution Foundation and Dolby Family Ventures led Vandria’s Series A closing, bringing the capital to CHF 28.3. With the money, the 2021 EFPL spin-out aims to advance its first in class mitophagy inducer VNA-318 that targets several neurodegenerative indications into clinical development.
OcuDyne Announces Positive Results for the OPTiC System™ 6-Month Clinical Trial in the Treatment of Geographic Atrophy
A medical device company utilizing a novel approach to treat ocular disease, announced today the successful completion of a pilot study using its proprietary OPTiC System for treating Age-Related Macular Degeneration (AMD).
Hackensack Meridian Mountainside Medical Center Chosen as One of Six Global Sites for Innovative MICRO 2.0 Clinical Trial
Mountainside is a site for the Genetesis MICRO 2.0 Clinical Trial, advancing non-invasive cardiac diagnostics to evaluate coronary microvascular dysfunction. This study explores how magnetocardiography could revolutionize heart condition diagnosis and management.
Adding anti-clotting drugs to stroke care ineffective, clinical trial finds
Opeolu Adeoye, MD a professor of emergency medicine at Washington University School of Medicine in St. Louis, led a national clinical trial that found that two anti-coagulant medications are ineffective at improving post-treatment outcomes for stroke patients.
Jonathan H. Sherman, MD, FAANS, FCNS, FACS, joins Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School, and Robert Wood Johnson University Hospital as Chief of Neurosurgical Oncology
Rutgers Cancer Institute, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, have appointed Jonathan H. Sherman, MD, FAANS, FCNS, FACS as chief of Neurosurgical Oncology at Rutgers Cancer Institute.
SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.
UNM Cancer Center Opens Ovarian Cancer Clinical Trial Using HIPEC Surgery
The University of New Mexico Comprehensive Cancer Center has opened a clinical trial that applies hyperthermic intraperitoneal chemotherapy (HIPEC) — a proven surgical technique that is used in digestive system cancers — to ovarian cancer.
First Patient Dosed in Phase 2 Clinical Study of Palatin’s Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (ClinicalTrials.gov Identifier: NCT06565611).
Moffitt Researchers Develop New Chemical Method to Enhance Drug Discovery
Moffitt Cancer Center researchers have developed a novel reagent that enhances the precision of drug synthesis. This innovative method, published in Nature Communications, introduces a new sulfur fluoride exchange (SuFEx) reagent that allows for highly controlled production of crucial sulfur-based molecules, including sulfinamides, sulfonimidamides and sulfoximines.
Phase 1 BAFF CAR T clinical trial for patients with relapsed and refractory multiple myeloma underway at UH Seidman Cancer Center
University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial. He says in the two years since the foundational pre-clinical work was completed, the team has shown that it’s feasible to manufacture BAFF CAR T-cells for human subjects.
New brain-computer interface allows man with ALS to ‘speak’ again
A brain-computer interface developed by UC Davis Health accurately translates brain signals into speech. The device implanted in the brain of a man with ALS is the most accurate system of its kind.
New Study Aims to Improve Bladder Cancer Treatment with High-Dose Intravenous Vitamin C
Researchers at The University of Kansas Cancer Center have secured a $3.6 million grant from the U.S. Department of Defense to study high-dose intravenous Vitamin C for treating muscle-invasive bladder cancer. This type of cancer occurs when cancer cells spread to the muscle layer of the bladder wall.
NUS researchers discover dual benefits of naturally occurring supplement on sleep and gut health
National University of Singapore (NUS) nutritionists have found that 5-Hydroxytryptophan (5-HTP) supplementation can improve sleep quality in Singaporean older adults, particularly in individuals with poor sleep patterns, and manage their gut microbiome composition.
New medication for stress urinary incontinence? Investigational drug shows promise
An investigational medication designated TAS-303 shows efficacy and safety in treatment of women with stress urinary incontinence (SUI), reports a placebo-controlled clinical trial in the August issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds
• 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment
• Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence
UNC Health Researchers Present Preliminary Data on Weight Loss Drugs on Alcohol Addiction
Christian Hendershot, PhD, associate professor of psychiatry and director of the Clinical and Translational Addiction Research Program at the UNC School of Medicine, presented early findings from the first completed randomized controlled trial of semaglutide for reducing alcohol consumption in heavy drinkers.
Researchers report first effective use of immunotherapy for most common subtype of colorectal cancer
These clinical trial results point to the first safe and effective use of immunotherapy for patients with microsatellite stable colorectal cancer, the most common subtype of the disease. The encouraging results of this phase I trial have prompted Dana-Farber investigators to move forward with a phase III trial of this immunotherapy combination.
Modifying homes for stroke survivors saves lives, extends independence
Researchers at Washington University School of Medicine in St. Louis have found that safety interventions – such as walkers, grab bars, ramps and other home modifications – allow many stroke survivors to keep living independently in their homes and may reduce their risk of death.
Anti-inflammatory drug celecoxib could reduce risk of colon cancer recurrence for a subset of patients
An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.
Clinical trial shows promising results in a two-drug combination that curbs methamphetamine use
A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment. To date there is no FDA-approved medication for it.
Neurent Medical Announces Publication of Positive Long-Term Results from Study on Chronic Rhinitis Treatment
Recent study confirms safety and efficacy of NEUROMARK® for chronic rhinitis
Drug Used to Treat Eczema May Provide Relief for Patients with Intensely Itchy Skin Diseases
Clinical Trial Finds Oral Medication Significantly Reduced Prurigo Nodularis and Chronic Pruritus of Unknown Origin Symptoms A drug approved to treat eczema provided significant improvement in the symptoms of patients with severe itching diseases that currently have no targeted treatments, according to a new study published in JAMA Dermatology.
Study Reveals Worse Clinical Outcomes in Breast Cancer Patients Who Reported Higher Pain and Stress
Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).
Trilaciclib use for prevention of hematological adverse events in chemotherapy: A meta-analysis of real-world studies and clinical trials
Background: Trilaciclib, a cyclin-dependent kinase (CDK)-4 and -6 inhibitor, is the only FDA-approved agent that preemptively protects hematopoietic stem cells from chemotherapy-induced myelosuppression (CIM) without compromising efficacy. It transiently arrests hematopoietic stem cells in the G1 phase, thus temporarily blocking progression…
RNA Inhibitor Is Shown Safe and Effective in Reducing a Wide Range of Cholesterol and Triglyceride Levels in the Blood in Mount Sinai-Led Clinical Trial
A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.
Pathways Study Genotype Data, Alliance A011502 Secondary Analysis Headline Roswell Park ASCO24 Presentations
New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week.
HSS Launches Clinical Trial to Address Post-Traumatic Osteoarthritis after ACL Revision Surgery
Up to 18% of patients undergoing ACL reconstruction experience graft failure and require revision surgery, which is known to increase the risk of developing post-traumatic osteoarthritis (PTOA).
CRISPR Gene Editing Leads to Improvements in Vision for People With Inherited Blindness, Clinical Trial Shows
BRILLIANCE trial results showed 11 out of 14 treated participants experienced some improvements in vision and quality of life measures. CRISPR-based therapy was found safe with no dose-limiting toxicities reported. Mass Eye and Ear researchers say their findings support continued…
Society for Clinical Trials Presents E-MOTIVE Trial with Prestigious David Sackett Trial of the Year Award
The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to the ”Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage (E-MOTIVE).”
Researchers Publish Final Results of Key Clinical Trial for Gene Therapy for Sickle Cell Disease
An international consortium published the final results of a key clinical trial of the gene therapy CASGEVY (exagamglogene autotemcel) for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).
Drug targeting clear cell renal cell carcinoma shows promising approach
In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC). Published in Clinical Cancer Research, the findings illustrate the potential of siRNA for cancer therapy.
Smart nanoparticles may be able to deliver drugs to heart after heart attack
Washington University’s Jianjun Guan to create custom nanoparticles to fight inflammation, fibrosis.
Molecular subtypes of advanced kidney cancer matter for treatment response
A new study published April 4 in Cancer Cell was led by Yale Cancer Center researchers, who collaborated with investigators nationally to differentiate the molecular subgroups of RCC tumors to better understand how their makeup might affect treatment responses.
L-Nutra’s Groundbreaking Study Revolutionizes Type 2 Diabetes Management Through Fasting Mimicking Nutrition Technology
Today, L-Nutra, the premier nutri-technology company, unveiled the results of a pioneering clinical trial, published in Diabetologia, which aims to redefine the approach to managing Type 2 Diabetes.
Tip Sheet: Weight loss drugs and cancer prevention, Fred Hutch at AACR, lymphedema Q&A — and new vice president and chief nursing officer
SEATTLE — April 3, 2024 — Below are summaries of recent Fred Hutchinson Cancer Center research findings, patient stories and other news. If you’re covering the American Association for Cancer Research (AACR) Annual Meeting, please see our list of and contact to set up interviews.
Combining epigenetic cancer medications may have benefit for colorectal cancers and other tumor types
A pair of medications that make malignant cells act as if they have a virus could hold new promise for treating colorectal cancers and other solid tumors, reports a study published today in Science Advances.